Gemcitabine-Capecitabine Chemotherapy Plus Intra-Arterial Epirubicin-Cisplatin in Pancreatic Cancer Patients after FOLFIRINOX First Line Chemotherapy : A Retrospective Analysis

Background: Most pancreatic cancer patients have disease recurrence/progression within 6 months from firstline chemotherapy end. Today, there is no a standard of care of second-line therapy. Materials (patients) and methods: We retrospectively collected data of 41 locally advanced/metastatic pancreatic cancer patients underwent to FOLFIRINOX first line chemotherapy and subsequently treated with Gemcitabine-Capecitabine chemotherapy plus Intraarterial Epirubicin-Cispatin (EC-GEMCAP). Results: Treatment was well tolerated, without dose reductions or delays. Hematologic and no hematologic grade 3-4 toxicities were 39% and 12.2%. Twenty, 2 and 12 patients obtained a stability/partial response/progression disease respectively, with a disease control rate in 22 patients. One patient with locally advanced disease underwent to radically surgery after 6 cycles of EC-GEMCAP. Median OS was 16.9 months (95% CI: 14.7-19.0) with OS rates at 6, 12 and 24 months of 95.1%, 80.5% and 31.7%. As regards second-line therapy, median OS was 8.9 months (95% CI: 6.9-10.9). OS rates at 6, 12 and 24 months were 61%, 80.5% and 31.7%. EC-GEMCAP median PFS was 4.1 months (95% CI: 3.1-5.1). PFS rates at 6 and 12 months were 41.5% and 19.5%. Conclusions: EC-GEMCAP proved to be a viable treatment in terms of toxicity and activity and it could be considered a therapeutic option also in poor performance status patients. Citation: Ginocchi L, Valsuani C, Sara L, Ceccherini C, Pedata M, et al. Gemcitabine-Capecitabine Chemotherapy Plus Intra-Arterial EpirubicinCisplatin in Pancreatic Cancer Patients after FOLFIRINOX First Line Chemotherapy: A Retrospective Analysis. J Cancer Sci. 2016;3(1): 5. J Cancer Sci 3(1): 5 (2016) Page 02 ISSN: 2377-9292 status ≤2 and adequate organ function (leukocyte count >3500/μL, haemoglobin ≥10.0 g/dL, serum creatinine <1.25 times upper limit of normal (ULN), transaminases and alkaline phosphatase <2.5 times ULN, bilirubin <1.5 times ULN). Staging included abdominal sonography, total abdomen and chest CT scan. Weight, performance status, CA 19-9 levels, and side effects were evaluated at study entry and after each cycle of regional therapy. An abdomen and chest CT scan was repeated every 3 treatment cycles. All patients gave their informed consent according to our institutional guidelines.


Introduction
Pancreatic cancer is the fourth leading cause of cancer death in men and women [1], the fifth in Europe [2].Surgery is the only potential curative therapy and radically resection represents an important prognostic factor with an overall survival advantage in negative surgical margins patients.Unfortunately, only 10-20% of cases meeting criteria for localized and resectable disease (stage I or II) following diagnosis, while 30-40% of patients have a locally advanced or borderline resectable disease [3] and are candidates in medical treatment, due to high risks of occult metastasis and positive surgical margin in case of surgery.The 50-60% of pancreatic cancer is already metastatic at diagnosis, thus medical therapy remains the only alternative that can prolong survival, which, however, does not exceed 11 months in the most active regimens (FOLFIRINOX) [4].Poor prognosis is mainly due to biological cancer aggressiveness and the low sensitivity to medical treatments, as systemic chemotherapy and radiotherapy.Previously studies showed pancreatic cancer sensitive to locoregional chemotherapy, due to increasing drug delivery [5][6][7][8][9] and consequent therapeutic efficacy strengthening in adjuvant and metastatic setting [10][11][12][13][14].
Although recent advances have improved outcomes in first line therapy, the vast majority of patients have disease recurrence or progression within 6 months, as concern the most active regimens FOLFIRINOX and nab-paclitaxel gemcitabine association [4,15].Today, there is no a standard of care in this setting and, unfortunately, treatment options in subsequent lines are limited, partly because patient clinical condition are deteriorated and chemotherapy is often burdened by significant side effects.
Relying on these premises and on the results of previously studies, which demonstrated efficacy and safety of intra-arterial chemotherapy, we retrospectively investigated the role of gemcitabine/ capecitabine plus intra-arterial epirubicin-cisplatin (EC-GEMCAP) after FOLFIRINOX first line chemotherapy.

Patients and Methods
Patients diagnosed with histologically or citologically surgical unresectable, locally advanced or metastatic pancreatic adenocarcinoma treated with FOLFIRINOX first line chemotherapy, from January 2011 to May 2014 where eligible for analysis.status ≤2 and adequate organ function (leukocyte count >3500/μL, haemoglobin ≥10.0 g/dL, serum creatinine <1.25 times upper limit of normal (ULN), transaminases and alkaline phosphatase <2.5 times ULN, bilirubin <1.5 times ULN).

They had to have age 18 to 75 years, ECOG performance
Staging included abdominal sonography, total abdomen and chest CT scan.Weight, performance status, CA 19-9 levels, and side effects were evaluated at study entry and after each cycle of regional therapy.An abdomen and chest CT scan was repeated every 3 treatment cycles.All patients gave their informed consent according to our institutional guidelines.

Treatment plan
On day 1, epirubicin 35 mg/mq and cisplatin 42 mg/mq were administered into celiac axis by bolus injection through a catether inserted in the femoral artery with the Seldinger method.
Capecitabine was given orally at the fixed dose of 650 mg/mq twice a day, on days 2-15.
Gemcitabine was administered on day 2 of each cycle at a starting dose of 1,000 mg/mq (intravenously, over 30 minutes).Treatment was repeated every 28 days, until evidence of progression disease or in event of unacceptable toxicity, or in case of patient request.
Adverse events were recorded according to the National Cancer Institute of Canada common toxicity criteria (NCIC-CTC).The epirubicin and/or cisplatin and/or capecitabine dosage was adjusted, delayed or omitted for toxic effects ≥ grade 2, based on protocol guidelines.
The response was evaluated after 3 cycles using abdomen and chest CT scan according to Response Evaluation Criteria in Solid Tumors (RECIST), 1.1 version.In cases of clinical response, independent of CT scan response, further 3 cycles were administered.

Statistics
Demographic and clinical characteristics were retrospectively recorded in database and summarized by medians and frequencies, as appropriate.based on imaging studies or death, whichever occurred first.OS was defined as the time interval between EC-GEMCAP beginning and time of death or last follow-up.

The primary end-point was PFS, defined as the time interval between EC-GEMCAP beginning and time of disease progression
PFS and OS were estimated by Kaplan-Meier method.
A clinical response was defined as an improvement in symptoms present at the beginning of treatment and was based on the investigators' evaluation.The objective response rate was calculated as the sum of complete and partial responses.The disease control rate was defined as the sum of complete and partial responses and stable disease.
SPSS for Windows version 13 was used for data analysis.

Results
From January 2011 to May 2014, we identified 41 patients with locally advanced or metastatic pancreatic cancer treated with FOLFIRINOX first line chemotherapy.A total of 80 cycles of FOLFIRINOX was administered, a median of 8 cycles for each patient (range 4-14).Ten patients also received loco-regional treatment: surgery, radiotherapy alone, radiotherapy associated to gemcitabine and termablation in 2, 2, 4 and 2 patients, respectively.Twenty seven patients (65.9%) progressed during or after first line treatment, with a median PFS of 5.2 months (range 1.6-15 months), while 14 patients (34.1%) had a stable disease.
At the beginning of second line treatment, 13 patients presented a stage III and 28 a stage IV disease.Median age was 56 years (range 42-71) and ECOG PS was 0/1/2 in 26, 8 and 7 patients (Table 1).

Discussion
Although many improvements have been made in the treatment of locally advanced pancreatic cancer, median overall survival reaches only 11.1 months for FOLFIRINOX and 8.5 months for nab-paclitaxel and gemcitabine [4,15], with recurrence or progression disease within 6 months from chemotherapy end.Since many patients are still fit, a second line treatment might be a reasonable choice after first line chemotherapy progression.Of course, a second line should take into account not only the previous treatments, but even patient physical condition, residual toxicity and potential side effects of other regimens.
Similarly, Caparello et al. conducted a prospective evaluation of 71 patients who underwent second line chemotherapy after modified FOLFIRINOX [28].Likewise to the report by the French colleagues, 66% of the progressed patients were able to start a second-line treatment, with a combination regimen in 52% of the cases.Unfortunately, second-line treatment did not provide such encouraging results, achieving a median PFS of only 2.5 months, a median OS of 6.2 months and even a lower disease control rate compared with the report published by Portal et al (34% vs 58%), after a median follow up of 20.1 months.Of note, baseline patient characteristics in the two series were similar, with the sole exception of PS, as we included only 2.8% of patients with ECOG PS 2. Also in 13 patients (18%) treated with gemcitabine plus nab-paclitaxel after FOLFIRINOX, results disappointed in terms of both activity (RR: 7%; DCR: 23%) and survival (median PFS: 1.95 months; median OS: 5.4 months).
Finally, anecdotal, the case of a patient with locally advanced disease underwent to radically surgery after 6 cycles of EC-GEMCAP therapy.The patients are still alive from the diagnosis of April 2012, with a OS of 51 months.Intra-arterial therapy could in fact contribute to a better cytoreductive effect for the purposes surgery, without giving sequelae of peritumoral tissues, as often happens after radiation therapy.
Of course, our trial has several limitations as the retrospective nature, the number of sample, the lack of a randomization design and quality of life evaluation, but showed than EC-GEMCAP may be a viable second line therapeutic alternative after FOLFIRINOX, also in patients without optimal general conditions.
On the basis of these results, considering the most effective therapeutic potential of new drugs, we have planned two studies of chemotherapy with nab-paclitaxel-gemcitabine plus Intra-arterial Epirubicin-Cispatin as neoadjuvant and second line therapy in pancreatic cancer patients.

Figure 2 :
Figure 2: OS and PFS since the beginning of EC-GEMCAP.

Table 1 :
Characteristics of the Patients and tumours.

Table 2 :
Safety evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 4.03.